97284 ⎘
Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL Framework region [FR]
Antibodies to granulocyte-macrophage colony stimulating factor and uses thereof
#602Chimeric antigen receptor
#603Colony stimulating factor 1 receptor (CSF1R) antibodies and immunoconjugates thereof
#604Composition for prophylaxis or treatment of IL-8 related diseases
#605BISPECIFIC ANTIGEN BINDING MOLECULES WITH TRIVALENT BINDING TO CD40
#606ENGINERRED ANTIBODIES TO HIV ENV
#607FILOVIRUS ANTIBODY
#608POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS
#609Anti-TREM-2 agonist antibodies
#610Anti-PSMA antibodies and use thereof
#611Immunoglobulin variable domains
#612Immunoglobulin variable domains
#613METHOD FOR IMPROVING AFFINITY OF ANTIBODY FOR ANTIGEN AND USE THEREOF
#614Blocking type PD-L1 single-domain camel antibody and application thereof
#615Immunoglobulin variable domains
#616Serine protease inhibitor kazal (SPIK) compositions and methods
#617FRIZZLED5 PROTEIN-BINDING AGENTS
#618ANTI-TIGIT ANTIBODIES AND METHODS OF USE
#619Humanized and chimeric monoclonal antibodies to CD47
#620Optimized gp41-Binding Molecules and Uses Thereof
#621Human IL-4R binding antibody, antigen binding fragment thereof, and medical use thereof
#622Multifunctional molecules that bind to calreticulin and uses thereof
#623CYTOTOXICITY-INDUCING THERAPEUTIC AGENT
#624METHOD FOR IMPROVING AFFINITY OF ANTIBODY FOR ANTIGEN AND USE THEREOF
#625Method for improving affinity of antibody for antigen and use thereof
#626Anti-PD1 antibodies and their use as therapeutics and diagnostics
#627UNIVERSAL OR NORMALIZED ANTIBODY FRAMEWORKS FOR IMPROVED FUNCTIONALITY AND MANUFACTURABILITY
#628Method of treating IgA nephropathy by administering altered antibodies which bind human a proliferation-inducing ligand (APRIL) protein
#629Anti-human 4-1BB antibodies and uses thereof
#630Mutations that drive VH4 antibody autoreactivity
#631Antibody compositions for disrupting biofilms
#632Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors
#633Monoclonal antibodies against human tim-3
#634Bispecific antigen binding molecules capable of specific binding to CD40 and to fap
#635Anti-transthyretin antibodies
#636Optimized nucleic acid antibody constructs encoding anti-respiratory syncytial virus (RSV) antibodies
#637Mesothelin-targeted trail trimer
#638Antibodies for treatment of cancer expressing claudin 6
#639Anti-Ly6G6D antibodies and methods of use
#640CD47 BINDING AGENTS
#641Anti-PHF-tau antibodies and uses thereof
#642Production of T cell retargeting hetero-dimeric immunoglobulins
#643Anti-rho GTPase conformational single domain antibodies and uses thereof
#644Antibodies, compositions, and immunohistochemistry methods for detecting C4.4a
#645HIGH-AFFINITY MYCOBACTERIUM TUBERCULOSIS CAPSULE-SPECIFIC HUMAN MONOCLONAL ANTIBODY
#646Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors
#647Human immunodeficiency virus neutralizing antibodies
#648Methods of binding amyloid beta protein having pyroglutamate at the third amino acid residue (3pE abeta) in vivo using anti-3pE abeta antibodies or antigen-binding fragments thereof
#649Anti-NGly-1 antibodies and methods of use
#650Amino acid sequences that modulate the interaction between cells of the immune system
#651Antibody libraries
#652Antibodies recognizing tau
#653Optimized variants of anti-VEGF antibodies
#654Conjugated biological molecules, pharmaceutical compositions and methods
#655PLAP-CAR-effector cells
#656MUC16 monoclonal antibody and uses thereof
#657Methods of lowering triglyceride levels with an ANGPTL8-binding antibody or antigen-binding fragment thereof
#658Immunoglobulins and uses thereof
#659Autoimmune suppressor and application thereof
#660Humanized and chimeric monoclonal antibodies to CD47
#661Anti-TIGIT antibodies and methods of use
#662Immunoglobulin variable domains
#663Bispecific HIV-1-neutralizing antibodies
#664Anti-VEGF antibodies and methods of use
#665Neutralizing antibodies to HIV-1 Env and their use
#666Neutralizing anti-influenza binding molecules and uses thereof
#667Neutralizing antibodies to ebola virus glycoprotein and their use
#668RADICALLY DIVERSE HUMAN ANTIBODY LIBRARY
#669Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
#670Antibodies and assays for CCL14
#671Antibodies to tumour antigens
#672Anti-CD25 antibody agents
#673CD3 ANTIGEN BINDING FRAGMENTS AND COMPOSITIONS COMPRISING SAME
#674ANTIBODIES AGAINST KIDNEY ASSOCIATED ANTIGEN 1 AND ANTIGEN BINDING FRAGMENTS THEREOF
#675Materials and methods for improved single chain variable fragments
#676Anti-CD25 for tumour specific cell depletion
#677Canine antibody therapeutic for treating cancer
#678METHOD FOR IMPROVING VEGF-RECEPTOR BLOCKING SELECTIVITY OF AN ANTI-VEGF ANTIBODY
#679METHOD FOR SELECTING ANTIBODIES WITH MODIFIED FCRN INTERACTION
#680Anti-CD25 for tumour specific cell depletion
#681Chimeric antigen receptors against multiple HLA-G isoforms
#682Humanized anti-claudin-1 antibodies and uses thereof
#683Humanized antibodies that recognize alpha-synuclein
#684POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS
#685RECRUITING AGENT FURTHER BINDING AN MHC MOLECULE
#686Antigen binding proteins specifically binding MAGE-A
#687ANTI-PD-L1 ANTIBODIES, COMPOSITIONS AND ARTICLES OF MANUFACTURE
#688ANTI-TIGIT ANTIBODIES AND METHODS OF USE
#689Compositions and methods for antibodies targeting BMP6
#690METHODS FOR PROMOTING PANCREATIC ISLET CELL GROWTH
#691Antibody fragment degrading and removing abnormal TDP-43
#692MODIFIED PROTEINS AND PEPTIDES
#693ANTI-TNFRSF25 ANTIBODIES
#694Targeted binding agents against B7-H1
#695Anti-siglec-5 antibodies and methods of use thereof
#696ANTIGEN BINDING PROTEINS TO ONCOSTATIN M (OSM)
#697Biopharmaceutical compositions comprising nucleic acids encoding IL-5 binding proteins
#698Anti-dengue virus antibodies having cross-reactivity to Zika virus and methods of use
#699METHOD FOR AFFINITY MATURATION OF ANTIBODIES
#700Anti-CD27 Antibody, Antigen-binding Fragment Thereof, and Medical Use Thereof
#701Anti-CD25 for tumour specific cell depletion
#702Anti-CD25 for tumour specific cell depletion
#703Anti-CD25 for tumour specific cell depletion
#704Anti-CD25 antibody agents
#705Anti-troponin T antibodies
#706Humanized tau antibodies in Alzheimer's disease
#707Antibodies to amyloid beta
#708Treatment and Prophylaxis of Amyloidosis
#709Antibodies with increased affinity for the epidermal growth factor receptor and fragments derived therefrom
#710NOVEL HUMANIZED ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR, ITS NUCELIC ACID SEQUENCE AND ITS PREPARATION
#711Anti-interleukin-33 antibodies and uses thereof
#712Antibodies to Feline McDonough Sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases
#713Antagonists targeting the TGF-β pathway
#714TRANSGENIC CHICKEN THAT PRODUCES HUMAN ANTIBODIES
#715Anti-CD25 antibody agents
#716Calcitonin gene-related peptide (CGRP) antagonist antibodies
#717Antibodies to surface determinants
#718Antibodies against OX-40 and uses thereof
#719DOSING FOR TREATMENT WITH ANTI-TIGIT AND ANTI-PD-L1 ANTAGONIST ANTIBODIES
#720PD-L1 antibody, antigen-binding fragment thereof and medical application thereof
#721Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
#722MONOCLONAL ANTIBODIES AGAINST HUMAN PD-L1 AND USES THEREOF
#723Anti-C10orf54 antibodies and uses thereof
#724Immunoglobulins and uses thereof
#725Fusion protein including BDNF
#726Anti-jagged antibodies and methods of use
#727Multispecific antibodies that target HIV GP120 and CD3
#728Animal Models and Therapeutic Molecules
#729Siglec-9-neutralizing antibodies
#730Acceptor Framework for CDR Grafting
#731IL-17 receptor A antigen binding proteins
#732Humanized anti-CCR7 receptor antibodies
#733Anti-CTLA-4 antibodies and methods of use thereof
#734Polynucleotides encoding IL33 antibodies and methods of using the same
#735Animal Models and Therapeutic Molecules
#736Animal Models and Therapeutic Molecules
#737NOVEL TNFR AGONISTS AND USES THEREOF
#738Single-domain antibodies and variants thereof against PD-1
#739Anti-Marinobufagenin Antibodies and Uses Thereof
#740ANTIGEN BINDING MOLECULES TO TIGIT
#741Antibody variants
#742ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
#743Animal Models and Therapeutic Molecules
#744Antibodies targeting CD137 and methods of use thereof
#745Anti-transthyretin antibodies
#746Anti-tryptase antibodies, compositions thereof, and uses thereof
#747Antibodies selective for cells presenting EGFR at high density
#748Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
#749Antibodies recognizing alpha-synuclein
#750VISTA antigen-binding molecules
#751Humanised ADAMTS13 binding antibodies
#752ANTI-CD25 ANTIBODIES AND THEIR USES
#753Anti-CD3epsilon antibodies
#754Anti-IL-17A antibodies and their use in treating autoimmune and inflammatory disorders
#755Bispecific HER2 antibodies and methods of use
#756Polypeptides which bind to interleukin-6 receptor (IL-6R)
#757Anti-IL13 antibodies and uses thereof
#758Antibody, composite, detection device and method using same
#759Serum albumin binders
#760Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors
#761Anti-coagulation factor VIII antibody and use thereof
#762Humanized antibodies against CEACAM1
#763AXL-specific antibodies and uses thereof
#764Anti-CD303 Monoclonal Antibodies
#765Bispecific antibody constructs and methods of use
#766PD-L1-specific antibodies and methods of using the same
#767Humanized antibodies that recognize alpha-synuclein
#768Dual conjugation process for preparing antibody-drug conjugates
#769Stable protein solution formulation containing high concentration of an anti-VEGF antibody
#770TIGIT antibody, antigen-binding fragment thereof, and medical use thereof
#771Dual specific antibodies for binding interleukin 4 (IL4) and interleukin 5 (IL5)
#772Serum albumin binding agents
#773Methods and compositions for treating and preventing disease associated with alpha-v beta-8 integrin
#774ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
#775MUC1* antibodies
#776ANTIBODIES AGAINST PD-L1
#777Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
#778Antagonists targeting the TGF-β pathway
#779Immunoglobulin variable domains
#780Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
#781Antibodies that bind colony stimulating factor 1 receptor (CSF1R)
#782Antibodies that target HIV GP120 and methods of use
#783Anti-MCAM Antibodies And Associated Methods Of Use
#784Polynucleotides encoding humanized antibodies against CEACAM1
#785Anti-PD1 antibodies and their use as therapeutics and diagnostics
#786Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
#787ANG2-BINDING MOLECULES
#788Anti-C5A antibodies
#789POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS
#790Heterodimeric antibodies that bind CD3 and CD38
#791BAFF-R BISPECIFIC T-CELL ENGAGER ANTIBODY
#792Humanized or chimeric CD3 antibodies
#793Biparatopic polypeptides antagonizing Wnt signaling in tumor cells
#794Antibody that binds to VEGF and IL-1beta and methods of use
#795PSEUDOMONAS AERUGINOSA PCRV BINDING SINGLE VARIABLE DOMAIN ANTIBODIES
#796Anti-PD-1 antibodies
#797Anti-tenascin C antibodies and uses thereof
#798COMPOSITIONS COMPRISING RESURFACED CELL-PENETRATING NANOBODIES AND METHODS OF USE THEREOF
#799Anti-human 4-1BB antibodies and uses thereof
#800STABLE AND SOLUBLE ANTIBODIES INHIBITING VEGF
#801TREATMENT WITH ANTI-VEGF ANTIBODIES
#802Methods of detecting pyroglutamate amyloid beta protein (3pE Aβ) using anti-3pE Aβ antibodies
#803IMMUNOGLOBULIN FRAMEWORKS WHICH DEMONSTRATE ENHANCED STABILITY IN THE INTRACELLULAR ENVIRONMENT AND METHODS OF IDENTIFYING SAME
#804Antibodies specific for IL-21 and uses thereof
#805Humanized anti-nuclear antibodies for targeting necrosis in cancer therapy
#806PERTUZUMAB VARIANTS AND EVALUATION THEREOF
#807Anti-PD-L1 antibodies and uses thereof
#808Antibody molecules which bind CD22
#809Composition and methods for treating snake envenomation
#810Method of generating a synthetic antibody library, said library and application(s) thereof
#811Glycosylation of variable immunoglobulin domains
#812Chimeric antigen receptor (CAR) comprising a CD19-binding domain
#813Non-Immunogenic Single Domain Antibodies
#814Humanized antibodies
#815Anti-transferrin receptor antibodies and methods of use
#816Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
#817ANTI-CD98 ANTIBODIES AND ANTIBODY DRUG CONJUGATES
#818Semi-synthetic nurse shark VNAR libraries for making and using selective binding compounds
#819Anti-IGF-I receptor antibodies, encoding nucleic acid molecules and methods of using said antibodies
#820Anti-CD3 antibodies
#821Methods of suppressing rheumatoid arthritis using an anti-IL-6 antibody
#822Antibody binding to FCRN for treating autoimmune diseases
#823Neutralizing anti-influenza binding molecules and uses thereof
#824T CELL RETARGETING HETERO-DIMERIC IMMUNOGLOBULINS
#825SIRP-α binding proteins and methods of use thereof
#826Modified variable domain molecules and methods for producing them
#827Deimmunized Serum-Binding Domains and Their Use in Extending Serum Half-Life
#828Anti-PD-L1 antibodies
#829Anti-transthyretin antibodies
#830Antibodies binding to TLR2/TLR4-interacting immunologically active polypeptide
#831Binding molecules specific for CD73 and uses thereof
#832ANTI-COMPLEMENT C1S ANTIBODIES AND USES THEREOF
#833Humanized antibodies which bind to human APRIL (“a proliferation-inducing ligand”)
#834ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
#835Antibodies binding to ILT4
#836Compounds
#837Anti-CD19 humanized antibody and immune effector cell targeting cd 19
#838Antibody capable of binding to norovirus, composite, detection device and method using the same
#839Antibody specifically binding to PAUF protein and use thereof
#840Anti-MIC antibodies and methods of use
#841Anti-transthyretin antibodies
#842ANTI-SIGLEC-8 ANTIBODIES AND METHODS OF USE THEREOF
#843CD3 binding antibodies
#844DNA molecules encoding anti-IL-33 antibodies
#845Carbohydrate antibodies, pharmaceutical compositions and uses thereof
#846Internalizing human monoclonal antibodies targeting prostate and other cancer cells
#847Epitope tag and method for detection and/or purification of tagged polypeptides
#848Method for treatment of an IL-17A-mediated disease through antibody administration specific to human IL-17A
#849ANTIBODIES RECOGNIZING MEDIN
#850Engineered stable CH2 polypeptides
#851Mice expressing a limited immunoglobulin light chain repertoire
#852Antibodies that bind human CD39 and inhibit ATPase activity of a soluble extracellular domain human CD39 polypeptide
#853BAFF selective binding compounds and related methods
#854Alpha-synuclein antibodies
#855Humanized antibodies that recognize alpha-synuclein
#856IMMUNOMODULATORY ANTIBODIES
#857IL-17 Receptor A antigen binding proteins
#858Anti-vista antibodies and fragments
#859Anti-NRP1 antibody screening method
#860Bispecific binding molecules binding to VEGF and Ang2
#861ANTI-MCAM ANTIBODIES AND ASSOCIATED METHODS OF USE
#862MODIFIED AMINO ACIDS COMPRISING TETRAZINE FUNCTIONAL GROUPS, METHODS OF PREPARATION, AND METHODS OF THEIR USE
#863ANTI-NR10 ANTIBODY AND USE THEREOF
#864Monoclonal antibodies to progastrin and their uses
#865Synthetic library of specific binding molecules
#866Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
#867NOVEL MULTI-SPECIFIC BINDING PROTEINS
#868Anti-marinobufagenin antibodies and uses thereof
#869ADAM9-binding molecules, and methods of use thereof
#870Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof
#871T cell recruiting polypeptides based on CD3 reactivity
#872Anti-indoleamine 2,3-dioxygenase 1 antibodies and diagnostic uses thereof
#873BINDING AGENTS
#874TIM-3 antibody, antigen binding fragment thereof, and medicinal uses thereof
#875Anti-tryptase antibodies, compositions thereof, and uses thereof
#876Anti-LSP1 antibody
#877Anti-PD-1 antibodies and compositions
#878Anti-podocalyxin antibodies and methods of using the same
#879Immunoglobulins and uses thereof
#880Anti-VLA-4 antibodies
#881Anti-SIRPA antibodies and methods of use thereof
#882Red blood cell targeted factor VIII and method of using the same
#883PLAZOMICIN ANTIBODIES AND METHODS OF USE
#884Monoclonal antibodies specific to the plexin-semaphorin-integrin (PSI) domain of RON for drug delivery and its application in cancer therapy
#885POLYPEPTIDE MODIFICATION METHOD FOR PURIFYING POLYPEPTIDE MULTIMERS
#886Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors
#887Anti-PD-L1 and IL-2 cytokines
#888Anti-B7H3 binding compounds and uses thereof
#889Opioid receptor binding agents and uses thereof
#890CD133-binding agents and uses thereof
#891Anti-FGFR3 antibodies and methods using same
#892CMET monoclonal binding agents, drug conjugates thereof and uses thereof
#893Anti-ICOS antibodies
#894Antibodies recognizing tau
#895Antibodies recognizing tau
#896Antibody to programmed death-ligand 1 (PD-L1) and use thereof
#897Anti-PD-1 nano-antibody and application thereof
#898Transgenic animal for production of antibodies having minimal CDRs
#899METHOD OF DETECTING CLEAVED SNAP25 IN TISSUE SAMPLES
#900THROMBIN ANTIBODY, ANTIGEN-BINDING FRAGMENT AND PHARMACEUTICAL USE THEREOF